Cargando…

Retinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia

Many cancers arise in a tissue stem cell, and cell differentiation is impaired resulting in an accumulation of immature cells. The introduction of all-trans retinoic acid (ATRA) in 1987 to treat acute promyelocytic leukemia (APL), a rare subtype of acute myeloid leukemia (AML), pioneered a new appro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Geoffrey, Hughes, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504222/ https://www.ncbi.nlm.nih.gov/pubmed/23213553 http://dx.doi.org/10.1155/2012/939021

Ejemplares similares

Induced differentiation of acute myeloid leukemia cells by activation of Retinoid X and Liver X Receptors
por: Sanchez, Patricia V., et al.
Publicado: (2014)

An exciting RXRA mutant revives interest in retinoids for acute myeloid leukemia
por: Qiu, Fang, et al.
Publicado: (2021)

Differentiation Therapy of Acute Myeloid Leukemia
por: Gocek, Elzbieta, et al.
Publicado: (2011)

Differentiation and Cell Survival of Myeloid Leukemia Cells
por: Studzinski, George P., et al.
Publicado: (2012)

Induced lineage promiscuity undermines the efficiency of all-trans-retinoid-acid-induced differentiation of acute myeloid leukemia
por: Tang, Yijia, et al.
Publicado: (2021)

Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy
por: Dobrotkova, Viera, et al.
Publicado: (2018)

Precision therapy for acute myeloid leukemia
por: Yang, Xue, et al.
Publicado: (2018)

Emerging therapies for acute myeloid leukemia
por: Saygin, Caner, et al.
Publicado: (2017)

Therapies for acute myeloid leukemia: vosaroxin
por: Sayar, Hamid, et al.
Publicado: (2017)

Why Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids
por: Chlapek, Petr, et al.
Publicado: (2018)

Role of autophagy in acute myeloid leukemia therapy
por: Zhang, Su-Ping, et al.
Publicado: (2013)

Advances in targeted therapy for acute myeloid leukemia
por: Yu, Jifeng, et al.
Publicado: (2020)

Resistance to targeted therapies in acute myeloid leukemia
por: Mecklenbrauck, Rabea, et al.
Publicado: (2022)

Targeted Therapy Development in Acute Myeloid Leukemia
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
por: Lin, Min, et al.
Publicado: (2018)

An Overview of Targeted Therapies in Acute Myeloid Leukemia
por: Turkalj, Sven, et al.
Publicado: (2023)

Differentiation therapy of myeloid leukemia: four decades of development
por: Madan, Vikas, et al.
Publicado: (2020)

Specific Uptake of Retinoids into Human Promyelocytic Leukemia Cells HL‐60 by Retinoid‐specific Binding Protein: Possibly the True Retinoid Receptor
por: Hashimoto, Yuichi, et al.
Publicado: (1988)

PB1901: NOT ALL VARIANTS OF ACUTE PROMYELOCYTIC LEUKEMIAS ARE RESISTANT TO RETINOIDS.
por: Dandwani, Mehndi, et al.
Publicado: (2023)

Endogenous and combination retinoids are active in myelomonocytic leukemias
por: di Martino, Orsola, et al.
Publicado: (2021)

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy
por: Kadia, Tapan Mahendra, et al.
Publicado: (2019)

Molecular landscape and targeted therapy of acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2018)

Targeting CLL-1 for acute myeloid leukemia therapy
por: Ma, Hongbing, et al.
Publicado: (2019)

Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
por: Miyamoto, Kenichi, et al.
Publicado: (2020)

Retinoic Acid Receptors in Acute Myeloid Leukemia Therapy
por: di Martino, Orsola, et al.
Publicado: (2019)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia
por: Obszański, Piotr, et al.
Publicado: (2022)

Recent advances in targeted therapies in acute myeloid leukemia
por: Bhansali, Rahul S., et al.
Publicado: (2023)

Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia
por: Tomizawa, Daisuke, et al.
Publicado: (2023)

Immune therapy: a new therapy for acute myeloid leukemia
por: Tian, Chen, et al.
Publicado: (2022)

Angiogenesis in Acute Myeloid Leukemia and Opportunities for Novel Therapies
por: Trujillo, Angelica, et al.
Publicado: (2012)

Maintenance therapy in acute myeloid leukemia: advances and controversies
por: Senapati, Jayastu, et al.
Publicado: (2023)

Prognosis and Therapy When Acute Promyelocytic Leukemia and Other “Good Risk” Acute Myeloid Leukemias Occur as a Therapy-Related Myeloid Neoplasm
por: Larson, Richard A., et al.
Publicado: (2011)

CXXC5 (Retinoid-Inducible Nuclear Factor, RINF) is a Potential Therapeutic Target in High-Risk Human Acute Myeloid Leukemia
por: Astori, Audrey, et al.
Publicado: (2013)

Why Topical Retinoids Are Mainstay of Therapy for Acne
por: Leyden, James, et al.
Publicado: (2017)

CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia
por: Yakymiv, Yuliya, et al.
Publicado: (2019)

Management of chronic myeloid leukemia in 2023 – common ground and common sense
por: Senapati, Jayastu, et al.
Publicado: (2023)

Acute Myeloid Leukemia: Is It T Time?
por: Khoud, Meriem Ben, et al.
Publicado: (2021)

Retinoids in Oncology
por: Rustin, G.J.S.
Publicado: (1994)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9ahd8jjafs3jl9r4ig2d2e6ogt